Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AN-207
- Development stage
- Preclinical
- Lead developer
- Æterna Zentaris
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
AN-207 is a targeted cytotoxic peptide-drug conjugate (PDC) consisting of the superactive doxorubicin derivative 2-pyrrolino-doxorubicin (AN-201) covalently linked to the luteinizing hormone-releasing hormone (LHRH) agonist [D-Lys6]LHRH. Developed by Dr. Andrew V. Schally's laboratory in collaboration with Zentaris GmbH, the drug is designed to deliver a potent chemotherapeutic payload specifically to tumor cells expressing LHRH receptors (GnRHR). By utilizing the LHRH analogue as a carrier, AN-207 aims to increase antitumor efficacy while minimizing systemic toxicities, such as myelosuppression, typically associated with conventional anthracyclines. It has demonstrated significant growth inhibition in various LHRH receptor-positive experimental models, including breast, prostate, ovarian, endometrial, renal cell, and melanoma cancers.
- Other names
- 2-pyrrolino-doxorubicin-LHRH conjugate[D-Lys6]LHRH-AN-201 conjugatecytotoxic LHRH analogue AN-207
02
Targets
DNATOP2A (DNA topoisomerase II)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on AN-207.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AN-207.